Contact us 24/7

IDX 184 Clinical Drug Trials

Idenix Halts Development of IDX 184

Idenix, a Massachusetts pharmaceutical company, has halted development of their experimental Hepatits C treatment IDX 184 amid reports of heart and kidney injuries in clinical trials for the drug.

In August 2012, the U.S. Food and Drug Administration (FDA) placed IDX184 on partial clinical hold after a patient died of heart failure during a clinical trial for a similar drug, BMS-986094.

In February 2013, Idenix announced it would discontinue clinical development of IDX184 altogether.

IDX 184 LINKED TO KIDNEY AND HEART PROBLEMS

Side effects associated with IDX 184 may include:

  • Fatigue
  • Nausea/vomiting
  • Shortness of breath
  • Decreased urine production
  • Kidney damage
  • Renal Failure
  • Swelling of the legs
  • Feelings of anxiety
  • Heart palpitations
  • Chest pain
  • Abnormal heart rhythm

IDX 184 CLINICAL DRUG TRIAL LOCATIONS

  • Phoenix, Arizona
  • Los Angeles, California
  • Sacramento, California
  • San Diego, California
  • San Francisco, California
  • Denver, Colorado
  • Bradenton, Florida
  • Orlando, Florida
  • Marietta, Georgia
  • Saint Louis, Missouri
  • Nashville, Tennessee
  • San Antonio, Texas
  • Salt Lake City, Utah
  • Newport News, Virginia
  • Richmond, Virginia
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Haifa, Israel
  • Jerusalem, Israel
  • Nazaeth, Israel
  • Safed, Israel
  • TelAviv, Israel

HAVE YOU BEEN INJURED?

If you’ve been injured, we can help. Contact us